Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatic Clamp Pilot & Feasibility Study in NAFLD
NCT05724134Phase 1Completed
- Sponsor
- Columbia University
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of regular human insulin in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Columbia University. Primary endpoints: Plasma glucose (absolute values) at 425 months, Plasma glucose (relative/change) at 425 months and 4 more. Started Aug 2023; status: completed.
02
Drugs
regular human insulin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05724134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724134.